• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Gagnon Robert E.

    1/10/24 5:17:09 PM ET
    $BBLG
    Industrial Specialties
    Health Care
    Get the next $BBLG alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Gagnon Robert E.

    (Last) (First) (Middle)
    C/O BONE BIOLOGICS CORP
    BURLINGTON WOODS DR. SUITE 100

    (Street)
    BURLINGTON MA 01803

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Bone Biologics Corp [ BBLG ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/08/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Non-Employee Stock Option $4.68 01/08/2024 A 9 (1) 01/08/2034 Common Stock 9 $0.00 9 D
    Non-Employee Stock Option $4.68 01/08/2024 A 8.006 (2) 01/08/2034 Common Stock 8,006 $0.00 8,015 D
    Explanation of Responses:
    1. This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable on the date of the next annual meeting of the stockholders of the Company following the grant date.
    2. This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, 2,003 options are immediately exercisable with the remaining 6,003 options vesting and becoming exercisable in three equal installments on 3/12/2024, 6/12/2024, and 9/12/2024.
    /s/ Robert E. Gagnon 01/10/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BBLG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BBLG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BBLG
    Leadership Updates

    Live Leadership Updates

    See more
    • Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

      Brings 30+ years of commercial experience in the orthopedic and spine industry Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company's board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four. Mr. Meikle most recently was president and chief executive officer of Biosystems of New England, Inc., an orthopedic distribution company that he founded in 1992 and sold to Stryker Corporation in 2019. He

      10/21/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors

      Brings 20+ years of experience in finance and business operations at both public and private life sciences companies Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced that effective immediately Robert E. Gagnon has been named to the Company's board of directors. Mr. Gagnon fills the seat left by Erick Lucera, who has resigned effective upon Mr. Gagnon's appointment. The number of directors of Bone Biologics remains at four. Mr. Gagnon is currently chief financial officer of Remix Therapeutics, a clinical stage company focused on small molecule-mediated reprogramming of RN

      1/11/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care

    $BBLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Frelick Jeff

      4 - Bone Biologics Corp (0001419554) (Issuer)

      1/21/25 6:10:12 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Walsh Deina H

      4 - Bone Biologics Corp (0001419554) (Issuer)

      1/21/25 6:06:14 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Meikle Phillip Terry Ii

      4 - Bone Biologics Corp (0001419554) (Issuer)

      10/18/24 8:27:04 PM ET
      $BBLG
      Industrial Specialties
      Health Care

    $BBLG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

      Brings 30+ years of commercial experience in the orthopedic and spine industry Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company's board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four. Mr. Meikle most recently was president and chief executive officer of Biosystems of New England, Inc., an orthopedic distribution company that he founded in 1992 and sold to Stryker Corporation in 2019. He

      10/21/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

      Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, chief executive officer, will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York City. Bone Biologics' company presentation will be available here beginning on Monday, September 9th at 7:00 a.m. Eastern time. The presentation will be available on the company's website for a period of time here. Management is available throughout the conference for virtual one-on-one meetings. Institutional investors and industry professionals can regis

      9/4/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

      Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 781,251 shares of its common stock having an exercise price of $2.43 per share, originally issued in March 2024. The issuance of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-276771). H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for t

      8/2/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care

    $BBLG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

      SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

      11/14/24 7:19:34 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

      SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

      11/13/24 11:14:34 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

      SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

      6/28/24 4:15:43 PM ET
      $BBLG
      Industrial Specialties
      Health Care

    $BBLG
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Bone Biologics Corp

      DEF 14A - Bone Biologics Corp (0001419554) (Filer)

      4/23/25 8:00:36 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form PRE 14A filed by Bone Biologics Corp

      PRE 14A - Bone Biologics Corp (0001419554) (Filer)

      4/11/25 5:05:39 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 8-K filed by Bone Biologics Corp

      8-K - Bone Biologics Corp (0001419554) (Filer)

      4/1/25 5:15:18 PM ET
      $BBLG
      Industrial Specialties
      Health Care